Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 3/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14256398 | 1.00 | KCNE1 (0.45) | KCNE1KCNQ1TRPV1ACKR3POLB | |
| SCHEMBL4621868 | 0.89 | KMT2A (0.42) | KCNE1KCNQ1TRPV1ACKR3MAPT | |
| SCHEMBL7474303 | 0.89 | TRPV1 (0.46) | KCNE1KCNQ1TRPV1MAPT | |
| SCHEMBL7472708 | 0.87 | MAPT (0.48) | KCNE1KCNQ1TRPV1MAPT | |
| SCHEMBL7461292 | 0.85 | KMT2A (0.45) | KCNE1KCNQ1TRPV1POLB | |
| SCHEMBL7477203 | 0.85 | TRPV1 (0.42) | KCNE1KCNQ1TRPV1HSD17B10 | |
| SCHEMBL7468526 | 0.84 | KCNE1 (0.49) | KCNE1KCNQ1TRPV1CYP3A4 | |
| SCHEMBL7477208 | 0.83 | HSD17B10 (0.41) | KCNE1KCNQ1TRPV1MAPTCYP3A4 | |
| Hydrochloric Acid SCHEMBL7474459 | 0.83 | TRPV1 (0.41) | KCNE1KCNQ1TRPV1 | |
| SCHEMBL7472489 | 0.83 | KCNE1 (0.48) | KCNE1KCNQ1TRPV1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1170528-C | Use of inhibitors of KQT1 channel for the production of medicaments for the treatment of helminth and ectoparasite-related diseases | ���ĵ�˹ҩ��¹�����˾ | 2004-10-13 | — | — | CN | claimed |
| US-20020055537-A1 | Use of inhibitors of the KQT1 channel and methods of controlling and treating diseases caused by helminths and ectoparasites | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-05-09 | — | — | US | claimed |
| US-6335363-B1 | ADMINISTERING 4-(SULFONYLAMINO-)-CHROMANE DERIVATIVE AS INSECTICIDE, NEMATOCIDE, FUNGICIDE OR PESTICIDE FOR CROP PROTECTION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-01 | — | — | US | claimed |
| EP-1140042-B1 | UTILIZATION OF INHIBITORS OF THE KQT1 CHANNEL IN ORDER TO PRODUCE A MEDICAMENT FOR TREATING DISEASES WHICH ARE CAUSED BY PARASITIC HELMINTHS AND ECTOPARASITES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055537-A1 | Use of inhibitors of the KQT1 channel and methods of controlling and treating diseases caused by helminths and ectoparasites | KCNQ1, KCNQ2, KCNQ3 | KCNE1 17/4885KCNQ1 1/4885TRPV1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.